A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Recruiting now · Phase 1
Conditions studied: B-cell Non-Hodgkins Lymphoma (B-NHL)
In brief
This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (dose escalation) is to find a safe dose of REGN5837 when given in combination with odronextamab. The goal of the second part (dose expansion) is to use the REGN5837 drug dose found in the first part to see how well REGN5837 in combination with odronextamab works. The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (that could make the drugs less effective or could lead to side effects)
Key facts
- Study ID
- NCT05685173
- Run by
- Regeneron Pharmaceuticals
- People needed
- 107
- Starts
- 2023-04-20
- Expected to finish
- 2030-01-13
- Last updated by the study team
- 2026-05-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Gustave Roussy — Villejuif, Île-de-France Region, France (enrolling)
- Erasmus Medical Center Rotterdam — Rotterdam, South Holland, Netherlands (enrolling)
- Amsterdam University Medical Centre, location AMC — Amsterdam, Netherlands (enrolling)
- Hospital Vall d'Hebron — Barcelona, Spain (enrolling)
- University Hospital and Research Institute — Madrid, Spain (enrolling)
- Royal Cornwall Hospitals NHS Trust, Royal Cornwall Hospital — Truro, Cornwall, United Kingdom (enrolling)
- Southampton General Hospital — Southampton, Hampshire, United Kingdom (enrolling)
- Western General Hospital — Edinburgh, Scotland, United Kingdom (enrolling)
- The Christie NHS Foundation Trust — Manchester, United Kingdom (enrolling)
- City of Hope — Duarte, California, United States (enrolling)
- University of California Los Angeles (UCLA) Medical Center — Santa Monica, California, United States (enrolling)
- Norton Cancer Institute — Louisville, Kentucky, United States (enrolling)
- Massachusetts General Hospital — Boston, Massachusetts, United States (enrolling)
- Harvard Medical School - Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States (enrolling)
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey, United States (enrolling)
- NYU Langone Health Perlmutter Cancer Center — New York, New York, United States (enrolling)
- Icahn School of Medicine at Mount Sinai — New York, New York, United States (enrolling)
- UT Southwestern — Dallas, Texas, United States (enrolling)
- CHU de Bordeaux — Talence, New Aquitaine, France (enrolling)
- Hopital Saint Louis — Paris, France (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.